Inhibition of growth hormone release by naloxone in adult tourette's syndrome subjects

Reuven Sandyk, Colin R Bamford

Research output: Contribution to journalArticle

Abstract

Opiates and opioid peptides have been shown to stimulate the release of Growth hormone (GH) in the rat and naloxone was reported to block this response (Kato et al., 1978; Bruni et al., 1977). Studies in man, however, failed to demonstrate any changes of GH release to administration of opiates (Morley et al., 1980). Moreover, GH levels stimulated by arginine, sleep, exercise, L-dopa and hypoglycaemia are modestly or not at all inhibited by naloxone (Morley 1981; Grossman & Rees, 1983), suggesting that opioids are not important modulators of GH secretion in man. We have recently demonstrated a significant rise of GH following naloxone administration in young Tourette's syndrome (TS) subjects aged 6-12 years (Sandyk & Barnford, in press, a). We have extended our study to evaluate the effects of acute naloxone challenge on GH release in an older group of TS-patients and in a small group of non-TS disease controls (6 narcoleptics). Following an overnight fast, naloxone (1.2 mg I.M.) was administered at 12:00 p.m. to six unmedicated TS patients aged 16-68 years (5 males, 1 female). Blood levels of GH were drawn 30 minutes after naloxone administration. Basal levels were drawn just prior to the naloxone challenge. Results are given in Table 1. While in the young TS patients, acute naloxone challenge produced a significant rise in plasma GH levels (Sandyk & Bamford, in press, a), in the adult group, naloxone produced suppression of GH plasma levels in 4 patients within 30 minutes of administration. The control group did not show any response to naloxone which is consistent with the reported norm (Grossman & Rees, 1983). These findings (1) suggest alterations in opioid control of GH release in TS that are maturation-related, and (2) complement many other clinical physiological and biochemical phenomena in TS that are also maturation-related. A variety of studies have demonstrated the absence of any direct effect of the opioids on pituitary GH release (Wehrenberg et

Original languageEnglish (US)
Pages (from-to)45-46
Number of pages2
JournalInternational Journal of Neuroscience
Volume40
Issue number1-2
DOIs
StatePublished - 1988

Fingerprint

Tourette Syndrome
Naloxone
Growth Hormone
Opioid Analgesics
Opioid Peptides
Opiate Alkaloids
Inhibition (Psychology)
Biochemical Phenomena
Complement C2
Physiological Phenomena
Levodopa
Hypoglycemia
Arginine
Sleep
Exercise

Keywords

  • Growth hormone
  • Tourette's syndrome

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Inhibition of growth hormone release by naloxone in adult tourette's syndrome subjects. / Sandyk, Reuven; Bamford, Colin R.

In: International Journal of Neuroscience, Vol. 40, No. 1-2, 1988, p. 45-46.

Research output: Contribution to journalArticle

@article{23354b74c7074d0cb372db8346b73639,
title = "Inhibition of growth hormone release by naloxone in adult tourette's syndrome subjects",
abstract = "Opiates and opioid peptides have been shown to stimulate the release of Growth hormone (GH) in the rat and naloxone was reported to block this response (Kato et al., 1978; Bruni et al., 1977). Studies in man, however, failed to demonstrate any changes of GH release to administration of opiates (Morley et al., 1980). Moreover, GH levels stimulated by arginine, sleep, exercise, L-dopa and hypoglycaemia are modestly or not at all inhibited by naloxone (Morley 1981; Grossman & Rees, 1983), suggesting that opioids are not important modulators of GH secretion in man. We have recently demonstrated a significant rise of GH following naloxone administration in young Tourette's syndrome (TS) subjects aged 6-12 years (Sandyk & Barnford, in press, a). We have extended our study to evaluate the effects of acute naloxone challenge on GH release in an older group of TS-patients and in a small group of non-TS disease controls (6 narcoleptics). Following an overnight fast, naloxone (1.2 mg I.M.) was administered at 12:00 p.m. to six unmedicated TS patients aged 16-68 years (5 males, 1 female). Blood levels of GH were drawn 30 minutes after naloxone administration. Basal levels were drawn just prior to the naloxone challenge. Results are given in Table 1. While in the young TS patients, acute naloxone challenge produced a significant rise in plasma GH levels (Sandyk & Bamford, in press, a), in the adult group, naloxone produced suppression of GH plasma levels in 4 patients within 30 minutes of administration. The control group did not show any response to naloxone which is consistent with the reported norm (Grossman & Rees, 1983). These findings (1) suggest alterations in opioid control of GH release in TS that are maturation-related, and (2) complement many other clinical physiological and biochemical phenomena in TS that are also maturation-related. A variety of studies have demonstrated the absence of any direct effect of the opioids on pituitary GH release (Wehrenberg et",
keywords = "Growth hormone, Tourette's syndrome",
author = "Reuven Sandyk and Bamford, {Colin R}",
year = "1988",
doi = "10.3109/00207458808985726",
language = "English (US)",
volume = "40",
pages = "45--46",
journal = "International Journal of Neuroscience",
issn = "0020-7454",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Inhibition of growth hormone release by naloxone in adult tourette's syndrome subjects

AU - Sandyk, Reuven

AU - Bamford, Colin R

PY - 1988

Y1 - 1988

N2 - Opiates and opioid peptides have been shown to stimulate the release of Growth hormone (GH) in the rat and naloxone was reported to block this response (Kato et al., 1978; Bruni et al., 1977). Studies in man, however, failed to demonstrate any changes of GH release to administration of opiates (Morley et al., 1980). Moreover, GH levels stimulated by arginine, sleep, exercise, L-dopa and hypoglycaemia are modestly or not at all inhibited by naloxone (Morley 1981; Grossman & Rees, 1983), suggesting that opioids are not important modulators of GH secretion in man. We have recently demonstrated a significant rise of GH following naloxone administration in young Tourette's syndrome (TS) subjects aged 6-12 years (Sandyk & Barnford, in press, a). We have extended our study to evaluate the effects of acute naloxone challenge on GH release in an older group of TS-patients and in a small group of non-TS disease controls (6 narcoleptics). Following an overnight fast, naloxone (1.2 mg I.M.) was administered at 12:00 p.m. to six unmedicated TS patients aged 16-68 years (5 males, 1 female). Blood levels of GH were drawn 30 minutes after naloxone administration. Basal levels were drawn just prior to the naloxone challenge. Results are given in Table 1. While in the young TS patients, acute naloxone challenge produced a significant rise in plasma GH levels (Sandyk & Bamford, in press, a), in the adult group, naloxone produced suppression of GH plasma levels in 4 patients within 30 minutes of administration. The control group did not show any response to naloxone which is consistent with the reported norm (Grossman & Rees, 1983). These findings (1) suggest alterations in opioid control of GH release in TS that are maturation-related, and (2) complement many other clinical physiological and biochemical phenomena in TS that are also maturation-related. A variety of studies have demonstrated the absence of any direct effect of the opioids on pituitary GH release (Wehrenberg et

AB - Opiates and opioid peptides have been shown to stimulate the release of Growth hormone (GH) in the rat and naloxone was reported to block this response (Kato et al., 1978; Bruni et al., 1977). Studies in man, however, failed to demonstrate any changes of GH release to administration of opiates (Morley et al., 1980). Moreover, GH levels stimulated by arginine, sleep, exercise, L-dopa and hypoglycaemia are modestly or not at all inhibited by naloxone (Morley 1981; Grossman & Rees, 1983), suggesting that opioids are not important modulators of GH secretion in man. We have recently demonstrated a significant rise of GH following naloxone administration in young Tourette's syndrome (TS) subjects aged 6-12 years (Sandyk & Barnford, in press, a). We have extended our study to evaluate the effects of acute naloxone challenge on GH release in an older group of TS-patients and in a small group of non-TS disease controls (6 narcoleptics). Following an overnight fast, naloxone (1.2 mg I.M.) was administered at 12:00 p.m. to six unmedicated TS patients aged 16-68 years (5 males, 1 female). Blood levels of GH were drawn 30 minutes after naloxone administration. Basal levels were drawn just prior to the naloxone challenge. Results are given in Table 1. While in the young TS patients, acute naloxone challenge produced a significant rise in plasma GH levels (Sandyk & Bamford, in press, a), in the adult group, naloxone produced suppression of GH plasma levels in 4 patients within 30 minutes of administration. The control group did not show any response to naloxone which is consistent with the reported norm (Grossman & Rees, 1983). These findings (1) suggest alterations in opioid control of GH release in TS that are maturation-related, and (2) complement many other clinical physiological and biochemical phenomena in TS that are also maturation-related. A variety of studies have demonstrated the absence of any direct effect of the opioids on pituitary GH release (Wehrenberg et

KW - Growth hormone

KW - Tourette's syndrome

UR - http://www.scopus.com/inward/record.url?scp=0024007223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024007223&partnerID=8YFLogxK

U2 - 10.3109/00207458808985726

DO - 10.3109/00207458808985726

M3 - Article

VL - 40

SP - 45

EP - 46

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

SN - 0020-7454

IS - 1-2

ER -